Dermagraft (over 150 million 2012) and (100 million 2011) are up for grabs. Read Shire's quarterly reports, Shire is hurting and losing it's marketshare. Don't take my word for it read it yourself. There is very easy, low hanging fruit for Epifix to pick up within the next year.
My physician sources tell me that there is very high turnover at Shire and Organogensis. This is typically a sign of a demise or decline in sales/marketshare. A great opportunity for Epifix to take over the category.
Or you can follow the professional fake yahoo accounts. To make the analogy, it's like being at a nice party and a person is trying to point to somebody who passed gas and turn the discussion to who passed it.
Lets focus on the big picture instead of the minutia. MDXG is poised for significant growth.